FDA Reviewing Merck’s Allergy Therapy Meant To Reduce Allergic Reactions
CBS Philly (con't)
Affordable Care Act Updates: CBSPhilly.com/ACA
Health News & Information: CBSPhilly.com/Health
Get Breaking News First
WHITEHOUSE STATION, N.J. (AP) — Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, itching and other symptoms temporarily.
Merck’s latest application is for an allergy immunotherapy tablet for ragweed allergies that dissolves under the tongue. Patients in studies of the tablet took it daily for a year.
It could become an alternative to months of uncomfortable allergy shots. Both methods gradually desensitize the immune system to the substance triggering the allergic reaction.
In March, the Whitehouse Station, N.J., company said the FDA was reviewing its application for an immunotherapy tablet for grass pollen allergies.
Merck expects FDA rulings on both still-unnamed treatments in 2014’s first half.
(© Copyright 2013 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed.)